Cartherics Pty Ltd
3:45 PM - 4:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 103
Cartherics is an Australian biotech company developing a range of allogeneic (off-the-shelf) immune cell products for the treatment of cancer. It has a technology platform based on gene-edited stem cells (induced pluripotent stem cells, or iPSCs) that can be expanded and differentiated into functional immune cells. The platform is underpinned by multiple patents and patent applications, most of which are owned by the company. Its lead product, CTH-401 is an iPSC-derived natural killer (NK) cell for the treatment of ovarian cancer (and potentially a range of other solid tumors). The company anticipates filing an IND for CTH-401 and entering clinical trials in 2025.
Cartherics is led by an internationally recognized team, with scientific and business expertise in stem cells, immunology, clinical development and oncology. It recently moved into its own purpose-built R&D facility in Notting Hill, Victoria, Australia where it houses its ~45 staff and has facilities.
Cartherics is led by an internationally recognized team, with scientific and business expertise in stem cells, immunology, clinical development and oncology. It recently moved into its own purpose-built R&D facility in Notting Hill, Victoria, Australia where it houses its ~45 staff and has facilities.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2016
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Allogeneic Chimeric Antigen Cancer Therapy
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
